

**QIBA Volumetric CT Group 3A Update**  
Thursday, 30 January 2014 at 11:30 AM CT  
Call Summary

**In attendance**

*Maria Athelougou, PhD (Chair)*  
Hubert Beaumont, PhD  
Andrew Buckler, MS  
Alden Dima, MS

Marios Gavrielides, PhD  
Lubomir Hadjiiski, PhD  
Rudresh Jarecha, MBBS  
Adele Peskin, PhD

Daniel Sullivan, MD  
Ying Tang, PhD  
Pierre Terve, MSc

**RSNA**

Joe Koudelik  
Julie Lisiecki

**Update: Status of the Paper for the Pilot/Pivotal Challenge**

- The paper based on the first challenge (pilot + pivotal) is still with NIST under review.
  - The estimated review time is 4 weeks; Dr. Peskin to update the group on the next call.
- In efforts to work on a clinical challenge paper in tandem with the analysis, Mr. Buckler will send a preliminary draft of the clinical challenge paper to: Drs. Athelougou, Gavrielides, and Peskin, for initial review of adherence to FDA and NIST parameters.
  - Feedback on the clinical paper draft is welcome: [andrew.buckler@elucidbio.com](mailto:andrew.buckler@elucidbio.com).

**Update: Status of the Clinical Challenge as of 1/30/2014**

- There are 12 participating sites testing 13 algorithms.
- Analysis of the challenge data is underway, and a preliminary report is anticipated by the February 13<sup>th</sup> call.
- Final analysis will include an individual report for each participating algorithm, as well as a cross-algorithm comparison
- Questions or comments from challenge participants should be directed through RSNA staff to maintain anonymity.
- Reports will include analyses of RDG files, secondary and tertiary analysis, and individualized bias levels.
- It is estimated that individualized reports will be sent to participants in May 2014.

**Action items:**

- Dr. Athelougou will contact a MICCAI representative in order to invite her/him for a presentation about comparison of challenge methodologies concerning the statistical evaluation of algorithm results.
  - Mr. Buckler to send a preliminary draft of the clinical challenge paper to: Drs. Athelougou, Gavrielides, and Peskin, for initial review of adherence to FDA and NIST parameters.
- 

**Next call:** *Thursday, February 13, 2014 at 11:30 AM CT.*